Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 33Terminated 25Recruiting 25Unknown 14Active not recruiting 11Not yet recruiting 2Withdrawn 1Suspended 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 35Breast Neoplasms 30Prostatic Neoplasms 22Leukemia, Myeloid, Acute 20Colorectal Neoplasms 20Melanoma 17Pancreatic Neoplasms 16Glioblastoma 16Carcinoma, Non-Small-Cell Lung 16Neoplasm Metastasis 15Lung Neoplasms 13Brain Neoplasms 13Glioma 12Stomach Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myelodysplastic Syndromes 11Carcinoma, Hepatocellular 11Ovarian Neoplasms 10Multiple Myeloma 9Head and Neck Neoplasms 9Triple Negative Breast Neoplasms 8Lymphoma 8Carcinoma, Renal Cell 8Leukemia 7Sarcoma 6Rectal Neoplasms 6Hematologic Neoplasms 6Esophageal Neoplasms 6Uterine Cervical Neoplasms 5Recurrence 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Interventional × Neoplasms by Histologic Type × Clear all
NCT03722186 2021-03-22

Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Suspended
128 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Neoplasms by Histologic Type, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡